TD Cowen Begins Coverage on Palvella Therapeutics (NASDAQ:PVLA)

Investment analysts at TD Cowen initiated coverage on shares of Palvella Therapeutics (NASDAQ:PVLA) in a research note issued on Wednesday, MarketBeat.com reports. The firm set a “buy” rating and a $44.00 price target on the stock. TD Cowen’s target price would indicate a potential upside of 193.33% from the stock’s previous close.

Several other analysts have also weighed in on the company. Cantor Fitzgerald began coverage on Palvella Therapeutics in a research note on Wednesday, December 18th. They issued an “overweight” rating on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $38.00 price objective on shares of Palvella Therapeutics in a research note on Friday, January 10th.

Palvella Therapeutics Trading Up 1.6 %

PVLA opened at $15.00 on Wednesday. The firm has a market cap of $168.30 million, a PE ratio of -1.24 and a beta of 0.68. Palvella Therapeutics has a 52-week low of $6.20 and a 52-week high of $22.32.

Insider Activity at Palvella Therapeutics

In other news, Director George M. Jenkins purchased 4,000 shares of the business’s stock in a transaction dated Wednesday, December 18th. The shares were purchased at an average cost of $12.93 per share, with a total value of $51,720.00. Following the completion of the purchase, the director now owns 180,671 shares of the company’s stock, valued at $2,336,076.03. This trade represents a 2.26 % increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at this link. 6.39% of the stock is currently owned by insiders.

Palvella Therapeutics Company Profile

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc, formerly known as Pieris Pharmaceuticals Inc, is based in WAYNE, Pa.